PDCD1 and melanoma: A previous study revealed that PD-1+ sEVs from T and B cells and PD-L1+ sEVs from melanoma cells were independent biomarkers for predicting immunotherapy response, according to multivariant Cox-hazard regression analyses for both overall and progression-free survivals30.